Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma
نویسندگان
چکیده
منابع مشابه
Systemic therapy of soft tissue sarcoma: an improvement in outcome.
Systemic therapy for the majority of patients with soft tissue sarcoma who require treatment of advanced unresectable or metastatic disease remains very unsatisfactory. Ifosfamide and doxorubicin remain the only agents in routine use. Treatment is usually given with palliative intent, and single-agent doxorubicin is generally regarded as the drug of choice. Inevitably, there have been efforts t...
متن کاملMultidisciplinary management of pediatric soft-tissue sarcoma.
The management of pediatric soft-tissue sarcomas has improved drastically through the use of multimodal therapy. These tumors include rhabdomyosarcomas and nonrhabdomyosarcomas. Both are staged using physical, radiographic, and histologic evaluation, and both have intricate staging and grouping systems that correlate closely with prognosis. However, approaches to therapy for the two tumor types...
متن کاملSystemic Therapy for Advanced Soft Tissue Sarcomas
Soft tissue sarcomas (STS) are a rare, heterogeneous group of solid tumors in need of improved therapeutic options. First-line chemotherapy is considered the current standard of care for patients with advanced, symptomatic STS, but the median survival is only 8 to 12 months. Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient out...
متن کاملSystemic management strategies for metastatic soft tissue sarcoma.
Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management. In the metastatic setting, chemotherapy is the primary modality of therapy. Doxorubicin alone or in combination with ifosfamide or dacarbazine has been the backbone of therapy since the 1970s. There is considerable activity for gemcitabine and docetaxel in leiomyosarcoma an...
متن کاملResectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: Which Patients Benefit from Adjuvant Radiation Therapy and How Much?
It remains unclear which children and adolescents with resected nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) benefit from radiation therapy, as well as the optimal dose, volume, and timing of radiotherapy when used with primary surgical resection. This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence ra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2020
ISSN: 1718-7729
DOI: 10.3747/co.27.5481